Pediatric AML

Constitutes a minor portion of all pediatric malignancies.

Has a low rate of event free survival and a high incidence of relapse when treated with traditional cytotoxic chemotherapy.

Incidence in children younger than 15 years seven per 1 million.

Accounts for one fourth of cases of pediatric acute leukemia.

Recent trials have achieved five year event-free survival rates ranging from 49-63%, with a relapse rate of 30%.

Outcomes in children with high risk features are significantly inferior to outcomes in children with favorable risk disease despite increased intensification of therapy, and HSCT.

Leave a Reply

Your email address will not be published. Required fields are marked *